Literature DB >> 6283072

The interaction between aminoquinolines and presynaptically acting neurotoxins.

L L Simpson.   

Abstract

Chloroquine and hydroxychloroquine block neuromuscular transmission in isolated tissues from mouse, rat, guinea pig and chick. Blockade is associated with depressed muscle responses to potassium and abolished muscle responses to nicotinic cholinergic agonists. Within certain time and concentration limits, the blocking effects of chloroquine and hydroxychloroquine are reversible. Both drugs antagonize the onset of paralysis caused by botulinum neurotoxin types A and B, but neither drug antagonizes tetanus toxin or beta-bungarotoxin. The ability of chloroquine and hydroxychloroquine to antagonize botulinum toxin is not due to blockade of nicotinic cholinergic receptors. At concentrations that produce neuromuscular blockade, d-tubocurarine does not antagonize botulinum toxin types A and B. Chloroquine causes botulinum toxin to remain at an antitoxin sensitive site. These data could mean that chloroquine acts at the cell membrane to inhibit toxin binding or internalization, or that it acts in the cell interior to inhibit lysosomal processing of toxin. Whatever its action, chloroquine is the most effective antagonist of botulinum toxin yet described.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6283072

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  13 in total

1.  Effect of pH on the interaction of botulinum neurotoxins A, B and E with liposomes.

Authors:  C Montecucco; G Schiavo; B R Dasgupta
Journal:  Biochem J       Date:  1989-04-01       Impact factor: 3.857

2.  Effects of hydroxamate metalloendoprotease inhibitors on botulinum neurotoxin A poisoned mouse neuromuscular junctions.

Authors:  Baskaran Thyagarajan; Joseph G Potian; Carmen C Garcia; Kormakur Hognason; Katerina Capková; Scott T Moe; Alan R Jacobson; Kim D Janda; Joseph J McArdle
Journal:  Neuropharmacology       Date:  2010-03-06       Impact factor: 5.250

3.  A preclinical evaluation of aminopyridines as putative therapeutic agents in the treatment of botulism.

Authors:  L L Simpson
Journal:  Infect Immun       Date:  1986-06       Impact factor: 3.441

Review 4.  Botulinum neurotoxin type A free of complexing proteins (XEOMIN) in focal dystonia.

Authors:  Wolfgang H Jost; Jörg Blümel; Susanne Grafe
Journal:  Drugs       Date:  2007       Impact factor: 9.546

5.  Purification of the putative alpha-latrotoxin receptor from bovine synaptosomal membranes in an active binding form.

Authors:  H Scheer; J Meldolesi
Journal:  EMBO J       Date:  1985-02       Impact factor: 11.598

Review 6.  Tetanus and botulinum neurotoxins: mechanism of action and therapeutic uses.

Authors:  R Pellizzari; O Rossetto; G Schiavo; C Montecucco
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-02-28       Impact factor: 6.237

Review 7.  The zinc-dependent protease activity of the botulinum neurotoxins.

Authors:  Frank J Lebeda; Regina Z Cer; Uma Mudunuri; Robert Stephens; Bal Ram Singh; Michael Adler
Journal:  Toxins (Basel)       Date:  2010-05-07       Impact factor: 4.546

8.  Botulinum neurotoxins B and E translocate at different rates and exhibit divergent responses to GT1b and low pH.

Authors:  Shihu Sun; William H Tepp; Eric A Johnson; Edwin R Chapman
Journal:  Biochemistry       Date:  2012-07-02       Impact factor: 3.162

9.  Interaction of 125I-labeled botulinum neurotoxins with nerve terminals. II. Autoradiographic evidence for its uptake into motor nerves by acceptor-mediated endocytosis.

Authors:  J D Black; J O Dolly
Journal:  J Cell Biol       Date:  1986-08       Impact factor: 10.539

Review 10.  Bacterial toxins: cellular mechanisms of action.

Authors:  J L Middlebrook; R B Dorland
Journal:  Microbiol Rev       Date:  1984-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.